Tickwind
TodayOpportunitiesMarketsAI Chat
EN
Log inSign up
Tickwind

Read every tick. See where the market's blowing.

  • X
  • TelegramChinese
  • Newsletter

Product

  • Markets
  • Theme Zones
  • All stocks
  • Compare
  • Hot stocks
  • Opportunities
  • News
  • Discussion
  • Watchlist
  • What's new

Account

  • Settings
  • Newsletter
  • For writers
  • MCP server
  • Contact
  • Log in
  • Sign up
MarketsTheme ZonesAll stocksCompareHot stocksOpportunitiesNewsDiscussionWatchlistWhat's newSettingsNewsletterFor writersMCP serverContactLog inSign up

© 2026 Tickwind. Not investment advice.

Made for the curious investor.

Home/ALEC/vs peers

ALECAlector, Inc.vs its industry peers

A metric-by-metric comparison of Alector, Inc. against Biological Products, (No Diagnostic Substances) — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.

Full peer comparison
Peers: same SEC industry (Biological Products, (No Diagnostic Substances))
CompanyMarket capP/E (TTM)P/BP/SRevenue growth (YoY)Earnings growth (YoY)EBIT marginROEROICPiotroski F1y total returnDividend yield
ALECAlector, Inc.This$230M#8——10.9x#5-79.1%#8-20.2%#7-741.3%#7———42.1%#4—
SABSSAB Biotherapeutics, Inc.$285M#113.0x#31.3x#6—-100.0%#9138.9%#1—6.2%#1——-3.5%#7—
IPSCCentury Therapeutics, Inc.$274M#2—1.2x#52.5x#11556.8%#192.4%#2-15.8%#2-4.1%#2-9.3%#1—152.6%#1—
LCTXLineage Cell Therapeutics, Inc.$258M#3—4.2x#1317.7x#753.2%#3-241.4%#14-251.6%#6-104.3%#13——-47.8%#11—
OCGNOcugen, Inc.$258M#4——58.4x#98.8%#4-25.9%#8-1425.7%#8———-50.2%#12—
LXEOLexeo Therapeutics, Inc.$257M#5—1.1x#3393.3x#10—-1.7%#5-16706.0%#10-42.5%#9——-65.3%#15—
FATEFATE THERAPEUTICS INC$245M#6—1.6x#836.9x#8-51.2%#726.8%#4-2222.4%#9-88.8%#12-102.3%#3—62.9%#2—
CABACabaletta Bio, Inc.$242M#7—1.2x#4——-44.9%#11—-79.7%#10——-52.3%#13—
PALIPALISADE BIO, INC.$216M#91.9x#11.8x#9——-16.2%#6—-13.8%#4——-37.8%#10—
PLXProtalix BioTherapeutics, Inc.$209M#1011.3x#22.9x#104.0x#3-1.2%#5-325.2%#15-10.4%#1-9.2%#3-12.3%#23#19.3%#6—
IKTInhibikase Therapeutics, Inc.$208M#11—1.4x#7—-100.0%#9-75.4%#12—-31.5%#7——-8.0%#9—
ARTVArtiva Biotherapeutics, Inc.$206M#12—0.6x#1—-100.0%#9-28.3%#9—-24.1%#5——12.0%#5—
DTILPRECISION BIOSCIENCES INC$194M#1321.7x#43.7x#125.7x#4-50.1%#6-738.0%#16-152.2%#4-88.3%#11——-6.1%#8—
ACOGAlpha Cognition Inc.$180M#14—3.4x#1117.6x#6—-39.8%#10-221.7%#5-39.0%#8——44.0%#3—
IVVDInvivyd, Inc.$172M#15—1.0x#23.2x#2110.5%#269.1%#3-104.0%#3-29.0%#6——-63.5%#14—
LIMNLiminatus Pharma, Inc.$169M#16—563.0x#14——-187.8%#13—-3395.2%#14-170.3%#4—-96.2%#16—

Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-11-04.

Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice

ALEC's peers

SABSIPSCLCTXOCGNLXEOFATECABAPALIPLXIKTARTVDTILACOGIVVDLIMN
← ALEC overview